PARP1 and pulmonary arterial hypertension: As inhibition of PARP1 using olaparib is currently tested in patients with PAH (OPTION [Olaparib for PAH: a Multicenter Clinical Trial]; NCT03782818), the long-term efficacy, safety, and tolerability of PARP1 inhibition in preclinical models was not assessed.